• LAST PRICE
    0.4201
  • TODAY'S CHANGE (%)
    Trending Up0.0096 (2.3264%)
  • Bid / Lots
    0.4001/ 33
  • Ask / Lots
    0.4400/ 48
  • Open / Previous Close
    0.4203 / 0.4105
  • Day Range
    Low 0.4005
    High 0.4400
  • 52 Week Range
    Low 0.0706
    High 1.7000
  • Volume
    5,453
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.4105
TimeVolumeEMMA
11:34 ET52020.4005
11:41 ET2500.42005
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesEMMA
Emmaus Life Sciences Inc
20.3M
-1.2x
---
United StatesOBSV
Obseva SA
22.4M
-0.2x
---
United StatesFNCH
Finch Therapeutics Group Inc
23.5M
-0.2x
---
United StatesLABP
Landos Biopharma Inc
17.7M
-0.3x
---
United StatesCDAK
Codiak BioSciences, Inc.
27.6M
-1.3x
---
United StatesAGLE
Aeglea Bio Therapeutics Inc
30.1M
-0.4x
---
As of 2023-02-03

Company Information

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company that is engaged in the discovery, development, marketing and sale of treatments and therapies for rare and orphan diseases. The Company’s lead product, Endari was approved by the United States Food and Drug Administration (FDA) to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari has received Orphan Drug designation from the FDA and Orphan Medicinal designation from the European Commission. Endari’s safety profile was like the placebo and Endari was well-tolerated in pediatric and adult patients alike. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003 and ELS002. The Company’s subsidiaries include EMI Holding, Inc., Emmaus Medical, Inc., Emmaus Medical Japan, Inc., Newfield Nutrition Corporation, Emmaus Medical Europe Limited, Emmaus Medical Europe Limited and Emmaus Life Sciences, Co. Ltd.

Contact Information

Headquarters
21250 HAWTHORNE BOULEVARD, SUITE 800TORRANCE, CA, United States 90503
Phone
310-214-0065
Fax
310-214-0075

Executives

Chairman of the Board, Chief Executive Officer
Yutaka Niihara
Chief Financial Officer
Yasushi Nagasaki
Chief Operating Officer, Director
Willis Lee
Senior Vice President - Global Commercialization, Chief Information Officer
George Sekulich
Senior Vice President - Medical Affairs, Clinical, Regulatory
Charles Stark

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$20.3M
Revenue (TTM)
$15.5M
Shares Outstanding
49.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.55
EPS
$-0.36
Book Value
$-0.43
P/E Ratio
-1.2x
Price/Sales (TTM)
1.3
Price/Cash Flow (TTM)
---
Operating Margin
-62.97%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.